Skip to main content

Table 1 The comparisons between LPD and OPD from different aspects

From: Laparoscopic pancreaticoduodenectomy: are the best times coming?

Author

Study period (years)

Country

Study design

Number of patients

LPD/OPD

Operation time, mean ± SD/median (range), (min)

LPD/OPD

Length of stay, mean ± SD/median (range), (days)

LPD/OPD

Estimated blood loss, mean ± SD/median (range), (ml)

LPD/OPD

Pathology

Overall survival (month)/5-year survival rate

van Hilst et al. [24]

2016–2017

Dutch

PS,MC

50/49

410 (252–481)/274 (212–317)*

12 (7–21)/11 (7–24)

300 (200–438)/450 (300–1000)*

PDAC, IPMN, ampullary tumor, CC, DC, NET, other

–

Zhang et al. [17]

2014–2016

China

RS, SC

202/213

301 ± 175/320 ± 91

12.97 ± 7.21/19.18 ± 7.14*

194 ± 107/390 ± 301

–

–

Zimmerman et al. [28]

2014–2015

USA

RS, NSQIP

280/6336

421 (331.5–499)/354 (277–437.5)*

7 (6–12)/9 (7–13)*

–

–

–

Chen et al. [27]

2013–2017

China

RS, SC

47/55

410 ± 68/245 ± 70*

13 ± 4/18 ± 5.5*

210 ± 46/420 ± 50*

PDAC, IPMN, periampullary tumor, CC

–

Poves et al. [25]

2013–2017

Spain

PS, SC

32/29

486 (337–767)/365 (240–510)*

13.5 (5–54)/17 (6–150)*

–

PDAC, IPMN, ampullary tumor, SPT, NET, other

–

Palanivelu et al. [26]

2013–2015

India

PS, SC

32/32

359 ± 14/320 ± 13

7 (5–52)/13 (6–30)*

250 ± 22/401 ± 46*

Periampullary tumors

–

Meng et al. [15]

2010–2015

China

PS, SC

58/58

475.0 (420.0–546.3)/335.0 (275.0–405.0)*

14.0 (11.0–17.3)/13.0 (11.0–20.0)

200.0 (100.0–325.0)/220.0 (150.0–400.0)

Nonpancreatic periampullary adenocarcinomas

45/48

Tan et al. [18]

2009–2014

China

RS, SC

30/30

513.17 ± 56.13/371.67 ± 85.53*

9.97 ± 3.74/11.87 ± 4.72*

–

Mainly periampullary adenocarcinoma

–

Delitto et al. [19]

2010–2014

The USA

PS, SC

52/50

361 (–)/360 (–)

9.0 (–)/11.9 (–)*

260 (–)/518 (–)*

Periampullary adenocarcinoma

27.9/23.5

PDAC

20.7/21.1

Sharpe et al. [33]

2010–2011

The USA

RS, NCDB

384/4037

–

10 ± 8.0/12 ± 9.7*

–

PDAC

–

Kantor et al. [31]

2010–2013

The USA

RS, NCDB

828/7385

–

10 ± 9/12 ± 9*

–

PDAC (stage I–II)

20.7/20.9

Chapman et al. [20]

2010–2013

The USA

RS, MC

248/1520

–

10 (7.0–15.0)/10 (7.0–15.5)

–

PDAC

19.8/15.6#

Langan et al. [35]

2010–2013

The USA

RS, SC

28/25

355/347

7.10/9.44*

336 (100–1400)/454 (100–1200)

PDAC, CC, other

–

Croome et al. [21]

2008–2013

The USA

RS, SC

108/214

379.4 ± 93.5/387.6 ± 91.8

6 (4–118)/9 (5–73)

492.4 ± 519.3/866.7 ± 733.7*

PDAC

25.3/21.8

Zureikat et al. [23]

2008–2010

The USA

RS, SC

14/14

456 (334–583)/372.5 (290–628)

8 (5–28)/8.5 (–)

300 (150–1300)/400 (–)

–

–

Song et al. [22]

2007–2012

South Korea

RS, SC

97/198

480.4 ± 116.4/351.9 ± 83.3*

14.1 ± 7.7/20 ± 10.7*

592 ± 376/555 ± 462

Benign or low-grade malignant tumors

–

93/93

482.5 ± 117.6/347.9 ± 87.2*

14.3 ± 7.8/19.2 ± 8.8

609 ± 375/570 ± 448

PDAC and ampulla of Vater cancer

–

Asbun et al. [36]

2005–2011

The USA

RS, SC

53/215

541 ± 88/401 ± 108

8 ± 3.2/12.4 ± 8.5

195 ± 136/1032 ± 1151

PDAC, IPMN, other

–

Hakeem et al. [34]

2005–2009

The UK

RS, SC

12/12

–

14.9 ± 6.6/14.9 ± 5.7

–

Periampullary adenocarcinoma, common bile duct tumors

75%/50%

Khaled et al. [29]

2002–2015

The UK

PS, SC

15/15

470 (280-660)/310 (240-490)*

9.0 (7–20)/15.4 (8–49)*

300 (50-600)/620 (150–1200)*

Malignant lesions

67%/53%

Conrad et al. [30]

2000–2010

The USA

RS, SC

40/25

–

23 (9–311)/28 (11–179)

–

PDAC

35.5/29.6

Stauffer et al. [32]

1995–2014

The USA

RS, SC

58/193

518 (313–761)/375 (159–681)*

6 (4–68)/9 (4–71)*

250 (50–8500)/600 (50–7800)*

PDAC

32.07%/15.34%

Lee et al. [16]

1993–2017

South Korea

RS,SC

31/31

426.8 ± 98.58/355.03 ± 100.0*

14.74 ± 5.40/23.81 ± 11.63*

477.42 ± 374.80/800.00 ± 531.35*

Benign and borderline malignant Periampullary disease

–

  1. –, no data
  2. PDAC pancreatic ductal adenocarcinoma, IPMN intraductal papillary mucinous neoplasm, SPT solid papillary tumor, CC cholangiocarcinoma, DC duodenum carcinoma, NET neuroendocrine tumor, PS prospective study, RS retrospective study, MC multi-center, SC single center, NSQIP National Surgical Quality Improvement Program, NCDB National Cancer Database
  3. *P < 0.05
  4. #The study was performed among patients aged ≥ 75 years